--- a
+++ b/clusters/9knumclustersv2/clust_1401.txt
@@ -0,0 +1,40 @@
+Measurable disease confirmed by central lab at Screening, defined by at least  of the following:
+Measurable disease defined by laboratory test results
+Measurable disease defined as any of the following:
+Measurable, secretory disease as defined by any of the following:
+Subjects must have measurable disease defined as at least  of the following:
+Patients must have measurable disease defined by at least  of the following  measurements:
+Measurable disease defined as any of the following:
+Disease status as defined as.
+Measurable disease at Screening as defined by any of the following:
+Must have measurable disease defined by:
+Must have measurable disease defined by at least  of the following  measurements:
+Confirmed measurable MM based on the following:
+Have measurable disease by at least  of the following measurements:
+Criteria  Measurable disease with at least  of the following assessed within  days prior to randomization:
+Patient with measurable progressive disease defined by at least one of the following two measurements:
+Measurable disease at screening as defined per protocol.
+Measurable disease defined by  or more of the following:
+Measurable disease of MM as defined by at least ONE of the following:
+Patients with measurable disease defined as at least one of the following:
+Measurable disease defined by at least ONE of the following:
+Patient has measurable disease defined as any of the following:
+Measurable disease defined as one or both of the following
+Measurable disease with at least  of the following assessed within the  days prior to randomization:
+Measurable disease as indicated by  or more of the following:
+Must have had measurable disease, defined by at least  of the following  measurements:
+During the dose expansion part of the study patients must have measurable disease defined by at least  of the following  measurements:
+Must have measurable disease defined as:
+Patients with measurable disease defined as at least one of the following
+Measurable disease assessed by one of the following ? days prior to registration:
+For patients in the Phase II portion of the study, must have measurable disease defined by at least  of the following  measurements:
+Measurable disease, as defined by  or more of the following (assessed within  days prior to randomization):
+Measurable disease, as indicated by one or more of the following:
+Measurable disease defined as at least one of the following:
+Measurable disease defined as at least one of the following:
+Measurable disease defined as at least one of the following:
+Measurable disease, as defined by one or more of the following (assessed within  days prior to randomization):
+Symptomatic, histologically confirmed MM, based on IMWG guidelines. Patients must have measurable disease as defined by at least one of the following:
+Measurable disease, including at least one of the following:
+Histologically confirmed MM with measurable disease per IMWG guidelines as defined by at least  of the following:
+For Participants with MM, measurable disease defined as one of the following: